Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that it will issue its audited full year results for the year ended 31 March 2019 on Tuesday 9 July 2019.
An analyst briefing will take place at the offices of Walbrook PR, 4 Lombard Street, London, EC3V 9HD at 9.30am on Tuesday 9 July 2019.
The Company will also be hosting an afternoon presentation for investors on Tuesday 9 July 2019, where Jamal Rushdy, CEO, and Hilary Spence, CFO, will summarise the full year results and discuss:
· The Company and its operations;
· Underlying business trends;
· Growth strategy;
· The recent placing and open offer;
· Outlook and key milestones.
This investor event will take place at the Copper Bar, upstairs at Balls Brothers, 6 Adams Court, Old Broad St, London, EC2N 1DX at 4.30pm for a 4.45pm start. This will be followed by drinks and canapes, and a chance to network.
If you would like to register for either the analyst or investor presentation, please contact Walbrook PR on 020 7933 8780 or email [email protected]
Collagen Solutions Plc
Contact via Walbrook
Jamal Rushdy, CEO
Hilary Spence, CFO
Cenkos Securities plc (Nominated Adviser and Broker)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
Collagen Solutions (LON: COS) CEO Jamal Rushdy joined Steve Darling from Proactive to discuss the company releasing their financial numbers that show impressive double-digit sales growth.
Rushdy talks about the numbers and also their tissue division that continues to be a revenue driver.